AGYTF
vs
S&P 500
AGYTF
S&P 500
Over the past 12 months, AGYTF has underperformed S&P 500, delivering a return of +10% compared to the S&P 500's +18% growth.
Stocks Performance
AGYTF vs S&P 500
Performance Gap
AGYTF vs S&P 500
Performance By Year
AGYTF vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Allergy Therapeutics PLC
Glance View
Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.
